RTP Mobile Logo
Submitted by web@researchtop... on Thu, 07/25/2019 - 16:07
VPL119

Discussion with Benjamin Levy, MD and Raymond Lobins, DO

Track 1: Case: A man in his early 60s, a current smoker, with metastatic lung adenocarcinoma and a PD-L1 tumor proportion score (TPS) of 80% experiences a dramatic response to first-line pembrolizumab but a recurrence of small lymphocytic lymphoma (SLL) during therapy
Track 2: Activity and tolerability of immune checkpoint inhibitors alone or with chemotherapy as first-line therapy in patients with metastatic non-small cell lung cancer (NSCLC)
Track 3: Duration of therapy with immune checkpoint inhibitors
Track 4: Perspectives on the effects of recent advances in the management of lung cancer on the practice of oncology
Track 5: Potential correlation between recurrence of chronic lymphocytic leukemia or SLL and treatment with anti-PD-1/PD-L1 antibodies
Track 6: Case: A woman in her late 50s with a history of autoimmune uveitis is diagnosed with NSCLC and multiple metastases in the brain
Track 7: Side effects associated with whole-brain radiation therapy
Track 8: Use of immune checkpoint inhibitors for patients with preexisting autoimmune disorders
Track 9: Therapeutic options for patients with metastatic NSCLC in the second-line setting
Track 10: Results of the Phase III REVEL trial investigating ramucirumab with docetaxel as second-line therapy for patients with metastatic NSCLC
Track 11: Activity of ramucirumab in patients with squamous cell NSCLC and those with prior exposure to bevacizumab
Track 12: Side effects and tolerability of ramucirumab and bevacizumab
Track 13: Case: A man in his early 50s, a current smoker, with metastatic lung adenocarcinoma and a BRAF non-V600E tumor mutation receives first-line carboplatin/pemetrexed/pembrolizumab
Track 14: Hemoptysis as a presenting symptom of lung cancer
Track 15: Clinical care of patients with metastatic NSCLC and no identified targetable tumor mutations
Track 16: Novel agents and approaches under investigation for lung cancer
Track 17: Mechanisms of resistance to immunotherapy
Track 18: Monitoring for immune-related adverse events in patients receiving immune checkpoint inhibitors
Track 19: Case: A woman in her mid-50s with large cell neuroendocrine carcinoma of the lung and a solitary metastasis in the brain
Track 20: Perspective on the management of oligometastatic disease
Track 21: Therapeutic options for patients with metastatic large cell neuroendocrine carcinoma of the lung
Track 22: Management of metastatic small cell lung cancer in the second-line setting
Track 23: Case: A man in his early 80s with severe pulmonary fibrosis is diagnosed with metastatic NSCLC
Track 24: Challenges in the management of pulmonary fibrosis in elderly patients with lung cancer
Track 25: Biologic rationale for and emerging data with immune checkpoint inhibitors in combination with anti-angiogenic agents
Track 26: Benefits and challenges of integrating early palliative care into the management of metastatic lung cancer
Track 27: Case: A man in his late 60s with metastatic NSCLC with KRAS and p53 tumor mutations experiences disease progression on multiple lines of therapy
Track 28: Therapeutic approach for patients with metastatic NSCLC in the late-line setting
Track 29: Case: A woman in her early 20s initially diagnosed with unresectable Stage III NSCLC with mutations in ROS1 and p53 develops metastatic disease
Track 30: Activity and tolerability of crizotinib and lorlatinib in patients with metastatic NSCLC and ROS1 tumor mutations
Track 31: Sequencing therapies for patients with metastatic NSCLC and ROS1 tumor mutations

Discussion with Leora Horn, MD, MSc and Yanjun Ma, MD

Track 1: Case: A woman in her mid-70s with Stage IV lung adenocarcinoma and a PD-L1 TPS of 70% experiences a pathologic fracture of the right femur while receiving first-line pembrolizumab
Track 2: Pembrolizumab monotherapy versus carboplatin/pemetrexed/pembrolizumab as first-line therapy for patients with metastatic NSCLC and a high TPS
Track 3: Radiation necrosis as a potential cause of pathologic fractures
Track 4: Thyroid dysfunction and pancreatitis associated with pembrolizumab
Track 5: Case: A man in his early 50s with metastatic lung cancer of ambiguous histology experiences a dramatic response to first-line nab paclitaxel/carboplatin
Track 6: Utility of liquid biopsies in therapeutic decision-making for patients with metastatic lung cancer
Track 7: Therapy for patients with metastatic lung cancer and CNS metastases
Track 8: Therapeutic approach for patients with metastatic lung cancer of undetermined histology
Track 9: Second-line therapy for patients with metastatic lung cancer
Track 10: Case: A woman in her mid-80s with metastatic lung adenocarcinoma and a PD-L1 TPS of 30% receives pemetrexed/pembrolizumab and experiences dyspnea
Track 11: Perspective on the approach to metastatic lung adenocarcinoma in elderly patients
Track 12: Efficacy of ramucirumab as second-line therapy for patients with metastatic NSCLC
Track 13: REVEL: Results of a Phase III trial evaluating the addition of ramucirumab to docetaxel after disease progression on platinum-based therapy for patients with Stage IV NSCLC
Track 14: Comparison of the activity and tolerability of ramucirumab to that of bevacizumab in patients with metastatic squamous cell carcinoma of the lung
Track 15: Ongoing clinical investigation of novel combination approaches with immune checkpoint inhibitors and anti-angiogenic agents
Track 16: Case: A man in his mid-70s, a former smoker, with Stage III NSCLC initially treated with adjuvant chemoradiation therapy develops metastatic disease and is found to have a RET tumor mutation
Track 17: Effects of tumor mutation burden and PD-L1 expression on response to immune checkpoint inhibitors
Track 18: Perspective on the use of targeted therapy as first-line treatment for patients with metastatic NSCLC
Track 19: Sequencing targeted therapy and immune checkpoint inhibitors for patients with metastatic NSCLC and actionable tumor mutations
Track 20: Case: A woman in her early 60s with lung adenocarcinoma and oligometastatic disease in the brain receives first-line chemoradiation therapy
Track 21: Cardiomyopathy associated with checkpoint inhibitor therapy
Track 22: Prolonged responses to anti-PD-1/PD-L1 antibodies after cessation of therapy
Track 23: PD-L1 expression as a predictor of response to immune checkpoint inhibitors
Track 24: Case: A man in his early 70s with metastatic NSCLC develops a severe carboplatin-related allergy during treatment with carboplatin/nab paclitaxel/pembrolizumab
Track 25: Benefits of early palliative care in the management of metastatic NSCLC
 
CLINICAL INVESTIGATORS
 
Benjamin Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Medical Director
Thoracic Oncology Program
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial
Washington, DC
 
Leora Horn, MD, MSc
Associate Professor of Medicine
Clinical Director
Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee
 
CONSULTING ONCOLOGISTS
 
Raymond Lobins, DO
Hulston Cancer Center (CoxHealth)
Springfield, Missouri
 
Yanjun Ma, MD
Tennessee Oncology
Murfreesboro, Tennessee
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida